Cardiac Monitors

Osypka Medical, headquartered in Berlin, Germany, is a cardiovascular device manufacturer founded in 1986. The company specializes in non-invasive hemodynamic monitoring and temporary cardiac pacing systems. Its core technology platform, Electrical Cardiometry™ (EC™), provides continuous, non-invasive assessment of cardiovascular hemodynamics for critical care, perioperative, and emergency settings. The EC™ product portfolio includes the ICON® and ICONCORE® monitoring systems with disposable EC™ sensors. The company also manufactures temporary cardiac pacemakers under the PACE® brand, including Models 101, 203, and 300, for external pacing therapy and intrinsic rhythm assessment. Complementary product lines include temporary pacing leads (EndoStim®), myocardial electrodes (MyoStim®), and connecting cables (StimConnect®). Osypka offers the CORASIM® heart simulator for clinical training and research. The company maintains a robust educational platform through Osypka Meducate®, providing clinical training in electrical cardiometry and temporary pacing. Products are supported by published clinical evidence, including application in COVID-19 patient management. The company operates a distributor network and provides comprehensive technical support and service. All devices are designed for use in acute care, ICU, operating room, and emergency department environments.

TZ Medical, Inc. is a Portland, Oregon-based medical device manufacturer specializing in innovative solutions for cardiac monitoring, interventional cardiology, labor and delivery, and operating room applications. The company designs and produces devices including cardiac monitoring systems (TZ Monitoring Solutions), radial access procedural equipment (Cobra Board, Pannus Retention System, Runway Pro Wrist Stabilization System), and labor induction devices (Adjustable Tensioning System for cervical dilation). TZ Medical operates under a "Sparked By Your Ideas" philosophy, partnering with clinical professionals to develop practical, patient-focused solutions. The company serves acute care hospitals, cath labs, interventional radiology departments, electrophysiology labs, ICUs, and operating rooms across the United States. TZ Medical emphasizes customer support, competitive pricing, and tailored solutions for procurement needs. The company has been recognized as one of Oregon's 100 Best Companies to Work For (2017–2026). While specific regulatory certifications are not detailed on the primary homepage, the company manufactures Class II and Class III medical devices subject to FDA oversight. Products are distributed through hospital purchasing and materials management channels.

AirStrip Technologies develops clinical surveillance and alarm management software that consolidates siloed clinical data from EMRs, bedside monitors, and medical devices into vendor-agnostic mobile and web applications. The platform provides real-time patient monitoring with embedded waveforms, automated protocol management, and visual decision support across ICU, Emergency, Obstetrics, Cardiology, and Rapid Response units. Core capabilities include multi-patient monitoring (up to 40 patients per screen), diagnostic-quality 12-lead ECG capture with STEMI notifications, maternal and fetal waveform monitoring with real-time visualization, and comprehensive alarm triage and analytics. The software features digitized peer-reviewed clinical protocols, alarm trend analysis and responsiveness metrics, and context-aware clinical linking. AirStrip integrates with diverse hospital infrastructure systems while maintaining HIPAA compliance and meeting ISO 27001 security standards. The platform supports telemetry optimization workflows, door-to-balloon time reduction for acute coronary syndromes, and multi-unit alarm management at scale. Named one of TIME's World's Top HealthTech Companies in 2025 with an "outstanding" rating.

Wearlinq manufactures the eWave, a FDA-cleared 6-lead wireless cardiac monitoring system designed for mobile cardiac telemetry and extended Holter monitoring. The device is imperceptible, featuring skin-like electrodes and a 5-day battery life per charge, with continuous data transmission to a cloud platform. The eWave captures six distinct ECG leads wirelessly, eliminating traditional wires while delivering diagnostic-grade cardiac data. The company operates Wearlinq Labs, an IDTF (Independent Diagnostic Testing Facility) with 33 years of cardiology service experience, staffed by Certified Cardiographic Technicians providing 24/7 coverage. Wearlinq delivers high-quality cardiology reports within 2 days and produces STAT reports daily. The platform includes a mobile application enabling real-time access to EKG data, digital diary functionality to correlate symptoms with cardiac events, connectivity monitoring to ensure signal quality, and 24/7 patient concierge support. The company targets cardiology practices, outpatient facilities, and hospitals requiring remote cardiac monitoring capabilities. Wearlinq received FDA clearance for the eWave and recently raised $14 million in funding, indicating active development and market expansion in the cardiac monitoring sector.

EME Company is a veteran-owned medical device manufacturer based in Prairieville, Louisiana, specializing in high-quality disposable textile goods and consumables for hospitals and healthcare distributors. The company operates an in-house American manufacturing facility and produces four primary product lines: medical pouches (telemetry pouches and storage pouches with hook-and-loop closures in various configurations), maternal and infant care products (postpartum briefs, infant caps, secure belts), medical-grade ice bags for cold therapy in multiple sizes, and cardiology consumables (diagnostic recording paper, EKG electrodes, and Holter monitor supplies for cardiac monitoring). EME holds ISO 13485 certification (acquired in 2005, updated to 2015 version) and manufactures all products under strict quality control standards in the United States. The company serves hospitals, clinics, and medical distributors domestically and internationally, with a reputation for reliable supply chain management, accurate order fulfillment, and responsive customer service. Manufacturing capabilities include custom textile production, automated assembly (including automated fetal belt and telemetry pouch machines), and in-house quality assurance. EME has been in operation since at least 1989 and maintains long-standing relationships with healthcare facilities nationwide.

TreyMed, Inc. is a leading designer and manufacturer of intelligent and affordable respiratory monitoring sensors and devices, incorporated in 1996. The company specializes in proprietary, patented sensor systems for two core applications: gas analysis (capnography/CO2 monitoring) and airway flow/pressure measurement. TreyMed supplies both OEM components (modules and sensors) and complete stand-alone monitors to medical device manufacturers and healthcare providers worldwide. Products include the Sidestream CO2 Module (low-cost, high-performance NDIR sensors), EZ-FLOW patented airway flow sensors (neonate through adult), Respiratory Mechanics Module (advanced data acquisition), and the Metaphor™ volumetric CO2/O2 metabolic monitoring system. The company also offers CO2 sensor simulators for testing and development. TreyMed competes on quality, affordability, and rapid technical support, with a growing customer base that includes major OEM partners and international distributors across Asia and New Zealand.

Beurer is a German-engineered health and wellness company (established 1919) offering consumer personal medical devices and home-care products. Their primary product lines include blood pressure monitors (upper arm and portable models), TENS/EMS electrotherapy units for pain relief and muscle stimulation, infrared heat therapy lamps, personal EKG heart monitoring devices, heating pads, massage devices (fascia rollers, shiatsu foot warmers), and wellness accessories (manicure/pedicure kits, insect bite relief devices, ultrasonic cleaners, beauty mirrors, kitchen scales, and air purification/humidification systems). Products are marketed for home health monitoring, active recovery, pain management, and personal wellness. The company operates a direct-to-consumer e-commerce platform (shop-beurer.com) with free shipping on US orders over $99. Beurer emphasizes German engineering heritage and drug-free therapeutic approaches. Products appear to meet consumer-grade standards and are available in both English and Spanish markets.

Acarix AS is a cardiac diagnostics company specializing in point-of-care acoustic-based diagnostic solutions for early coronary artery disease (CAD) assessment. The company's flagship product, CADScor® System, uses highly sensitive acoustic technology and advanced computational processing to analyze coronary blood flow and calculate patient-specific CAD risk scores. The system provides non-invasive, radiation-free risk stratification for patients presenting with chest pain or shortness of breath, with demonstrated negative predictive value of at least 96%. CADScor® System has been deployed in over 60,000 patient assessments since 2017 and is supported by 15+ years of research and development covered by 45 patents. The technology has received FDA De Novo clearance as a diagnostic aid for symptomatic patients with suspected CAD and is CE-marked in accordance with EU MDR 2017/745. Clinical evidence from multiple published studies involving over 6,000 patients demonstrates the system's diagnostic performance and utility compared to standard stress testing. The platform enables immediate risk stratification at point of care, potentially reducing unnecessary advanced diagnostic procedures in up to 40% of patients. Acarix targets healthcare professionals and facilities seeking accessible, cost-effective cardiac risk assessment tools that can be deployed regardless of geographical location or socioeconomic constraints.

VasoMedical, Inc. is a cardiovascular technology company with nearly 40 years of experience in cardiac diagnostics and therapy. The company specializes in two primary product areas: Enhanced External Counterpulsation (EECP®) therapy systems and next-generation cardiac monitoring platforms. Their Lumenair™ EECP® system is deployed in over 600 clinics across 40+ countries and is used for non-invasive therapy to improve coronary circulation, helping patients with angina and heart failure improve exercise tolerance and quality of life. In cardiac monitoring, VasoMedical offers the ARCS cloud-native platform, an FDA-cleared system for Holter, Extended Holter, Event, and Multi-Channel Telemetry (MCT) monitoring. ARCS features artifact-reduction algorithms, unified workflow management, and high-volume scanning capabilities designed to reduce manual rework and accelerate turnaround times. The company has analyzed over 1 billion heartbeats and delivered 12+ million hours of cardiac monitoring data. VasoMedical also provides the Advanced Cardiac Therapy (ACT) Program, a comprehensive utilization and operations model to help health systems optimize EECP program performance across cardiology, rehabilitation, and administrative workflows. The company serves hospitals, cardiology practices, rehabilitation clinics, and health systems ranging from private practices to major healthcare networks. Products are supported by FDA clearance for monitoring algorithms and established reimbursement pathways. VasoMedical combines hardware, software, and operational consulting to address both clinical and workflow challenges in cardiac care.

SoftLink International is a healthcare IT company headquartered in India, founded in 1997, specializing in software solutions for hospital automation, clinical informatics, patient workflow management, and analytics. The company serves over 450 healthcare institutions across 15 countries, with significant deployments in the USA, Middle East, India, and Far East. Core product offerings include PANACEA (Hospital Information Management System/HIMS), a comprehensive EHR/EMR platform supporting full hospital digitization and paperless operations; Cardiology Solutions (CVIS—Cardiovascular Information System) providing multimodality viewing, cath lab inventory management, and research tools; Radiology Solutions delivering end-to-end PACS (Picture Archiving and Communication Systems) from single clinics to enterprise deployments; and TeleHealth Solutions functioning as standalone or integrated remote consultation platforms. The company maintains compliance certifications including FDA, HIPAA, ISO 9001, ISO 27001, DICOM, HL7, ICD-10, and IHE standards. SoftLink provides custom engineering, system integration, and data migration services. Known strengths include deep EHR/EMR integration experience (compatibility with EPIC, Cerner, and proprietary systems), support for non-DICOM modalities, and agile product innovation. The firm operates on a turnkey model, reducing dependency on third-party vendors. Clientele includes major hospital chains (Apollo, Fortis, Max Healthcare, Mount Sinai), government medical institutions (JIPMER), and specialty centers across multiple disciplines.

Since 1986, Jant Pharmacal Corporation has been a leading B2B supplier of point-of-care (POC) diagnostic tests and laboratory instrumentation to U.S. and international healthcare settings. The company operates two primary divisions: POC Division and Lab Division. The POC Division offers CLIA-waived rapid tests and analyzers for use in physicians' offices, clinics, urgent care centers, and hospitals under registered trademarks Accutest, Accustrip, and LipidPlus. Product categories include cardiac testing, colorectal cancer screening, drugs of abuse, hypothyroidism, infectious diseases, pregnancy & fertility, and urinalysis. The Lab Division provides integrated solutions for laboratory optimization, featuring clinical chemistry, hematology, immunoassay, toxicology, urinalysis, and molecular diagnostic systems with reagents and consumables. The company holds GPO supplier contracts with Vizient and Champs, representing over 500,000 members. Additionally, Jant offers laboratory consultation services including financial feasibility assessment, turn-key laboratory setup, CLIA compliance consultation, LCMS method development, and laboratory information system integration.

R&D Batteries, Inc. is a multi-million dollar battery assembler and distributor specializing in replacement batteries for medical equipment. The company maintains factory-direct relationships with premier cell manufacturers including Sanyo, Panasonic, Powersonic, Yuasa, FDK, Enersys, Sonnenschein, Varta, Saft, Energizer, and Renata. Their medical battery portfolio includes solutions for infusion pumps (Baxter Sigma Spectrum, Alaris Medley, ICU Medical Plum A+), defibrillators and AED systems (Physio-Control Lifepak, Zoll R Series, Cardiac Science PowerHeart), patient monitoring devices (GE Marquette, Philips AVALON FM20, Welch Allyn), and emergency medical equipment. Beyond medical batteries, R&D Batteries supplies replacement batteries for UPS backup systems, emergency lighting, communication devices, and other industrial applications. The company emphasizes engineering, testing, manufacturing, and distribution capabilities with ISO 13485 certification (MDSAP compliant), in-house production quality control, and direct supply-chain partnerships enabling competitive pricing and rapid fulfillment.

Retia Medical Systems develops cardiovascular surveillance software and hemodynamic monitoring solutions for intensive care, operating rooms, and perioperative environments. The company's core offering is the Argos® Cardiac Output Monitor, a bedside hemodynamic monitoring device that derives reliable cardiac output and cardiovascular insight from routine physiologic signals without requiring proprietary disposable sensors. The Argos Infinity™ platform extends this capability enterprise-wide, deploying the company's Multi-Beat Analysis (MBA) algorithm across hospital systems and tele-ICU environments to enable centralized cardiovascular surveillance and analytics. Retia's technology is designed to detect hemodynamic instability earlier than traditional vital sign monitoring, particularly in complex scenarios including arrhythmia, cardiogenic shock, low-flow states, and unstable blood pressure. The software integrates with existing monitoring and tele-ICU platforms, transforming real-time physiologic data into actionable clinical intelligence. Deployed in 75+ hospitals including major academic medical centers (Johns Hopkins, Duke Health, Cleveland Clinic, University Hospitals Cleveland, Texas Health Resources, UMC Health System, Rabin Medical Center), the solution has been validated in 14 peer-reviewed clinical studies. Retia received FDA 510(k) clearance for Argos Infinity. The company targets high-risk populations including cardiac and vascular surgery, sepsis, transplant, trauma, burns, and neurocritical care. Primary value propositions include elimination of disposable sensor costs, intuitive bedside workflow design, and system-wide scalability without infrastructure burden.

Element Science, Inc. is a San Francisco-based medical device startup founded in 2013, specializing in clinical-grade wearable solutions for cardiac care. The company's flagship product is the Jewel® Patch Wearable Cardioverter Defibrillator, an adhesive-based patch device designed to treat patients at temporary elevated risk of lethal heart rhythms and sudden cardiac arrest. Unlike traditional bulky defibrillator vests, Jewel® offers a sleek, comfortable, and discreet design that provides 24/7 cardiac monitoring and protection during critical transitions from hospital to home. The device leverages machine learning and data science algorithms to detect and treat dangerous arrhythmias. Element Science has received FDA approval, CE Mark, and UKCA Mark certifications for Jewel®, positioning it as the first and most innovative patch-based wearable cardioverter defibrillator on the market. The company is actively developing a broader pipeline of heart disease solutions that combine wearable technology with predictive analytics to improve patient outcomes and prevent sudden cardiac death.

C.R. Bard (now part of BD) is a diversified global medical technology company operating through multiple business segments: BD Interventional, BD Life Sciences, and BD Medical. The company manufactures and distributes an extensive portfolio of medical devices, consumables, and diagnostic solutions across vascular access, medication delivery, infection prevention, laboratory diagnostics, surgical instruments, and specialty medical equipment. Through the Medivance acquisition (2011), Bard offers the Arctic Sun™ Targeted Temperature Management system for precise patient temperature control in critical care settings. The company serves hospitals, healthcare systems, clinical laboratories, and other healthcare facilities with products spanning syringes and needles, catheters (central and peripheral), infusion systems, surgical mesh and grafts, diagnostic culture media, molecular testing systems, blood collection products, stents, and specialty equipment for urology, cardiology, gynecology, and interventional medicine. With thousands of SKUs across therapeutic areas including vascular surgery, gastrointestinal care, wound management, and microbiology solutions, Bard functions as a comprehensive B2B medical device and consumables supplier.

Ascom Holding AG is a Swiss-based global provider of integrated communication and collaboration solutions for healthcare, long-term care, and enterprise sectors. The company specializes in bridging digital information gaps with mission-critical, near real-time workflow solutions designed for highly mobile, time-sensitive clinical environments. Core offerings include nurse call systems, clinical alarm management, mobile devices (VoWiFi, IP-DECT), staff safety systems, activity monitoring, and IoT-enabled technical alarm integration platforms. Ascom's solutions support clinical surveillance, rapid response team coordination, and workplace safety across acute care hospitals, long-term care facilities, and industrial settings. The company operates subsidiaries in 19 countries and processes 1.3 million data points daily through its systems, enabling healthcare organizations to optimize operational efficiency, reduce alarm fatigue, and enhance patient and staff safety through interoperable, open-source compatible integrations.

VivaQuant, Inc. (operating as Rhythm Express) is a remote cardiac monitoring company specializing in portable, wireless ECG/cardiac monitoring solutions for healthcare providers and patients. Their flagship product, the RX-1 mini, is an all-in-one, water-resistant (IP64) wearable device designed for continuous cardiac monitoring with uninterrupted data collection. The device combines multiple monitoring capabilities in a single compact form factor, enabling seamless patient compliance through lifestyle-compatible design, including shower capability. The company serves over 600 clinics and healthcare facilities nationwide, with a track record of monitoring 600,000+ patients. Rhythm Express delivers comprehensive cardiac data analysis, including enhanced P-wave detection, with actionable reporting available typically within 24–48 hours and event notifications within 20 minutes. The platform integrates dual connectivity (cellular and Wi-Fi) for real-time data transmission and includes a cloud-based portal for clinician workflow integration. Business model offerings include subscription-based pricing, fee-for-service, and split-bill arrangements, designed to minimize upfront costs and provide predictable monthly pricing without hidden fees. The company provides 24/7 technical support and continuous device/software updates. Based in Arden Hills, Minnesota, VivaQuant delivers cardiac monitoring solutions positioned at the intersection of remote patient monitoring, home healthcare, and cardiology practice efficiency. Products are designed for both in-home patient monitoring and clinical practice settings.

Spectrum Dynamics Medical is a specialized medical device manufacturer focused on personalized molecular imaging and nuclear medicine applications. The company develops high-definition, solid-state nuclear imaging technology using proprietary 360° CZT (Cadmium Zinc Telluride) detector technology. Their portfolio includes the D-SPECT Series, an advanced digital SPECT imaging system designed for cardiology applications featuring rapid myocardial perfusion imaging (scan times as fast as 2 minutes), dynamic imaging for flow reserve calculation, and emission-based attenuation correction; and the VERITON-CT Series, the first ring-shaped SPECT/CT hybrid system enabling comprehensive total-body 3D imaging with an 80 cm bore size for expanded procedural capabilities. CZT solid-state detectors provide superior sensitivity and energy resolution compared to traditional NaI detectors, eliminating the need for photomultiplier tubes and enabling higher count rates. Spectrum Dynamics serves hospitals, cardiology clinics, diagnostic imaging departments, and nuclear medicine centers globally, with R&D facilities in Haifa, Israel and regional offices across North America, Europe, and Asia-Pacific.

Navi Medical Technologies is an Australian medtech company founded in 2017, specializing in innovative pediatric medical devices for critically ill newborns and children. The company addresses a critical gap in the market, as only 5% of FDA-approved devices are suitable for neonates. Navi's flagship product, the Neonav® ECG Tip Location System, uses real-time ECG surveillance technology and proprietary algorithms to enable non-invasive bedside verification of Central Vascular Access Device (CVAD) tip location in neonatal and pediatric patients. This addresses the high prevalence of CVAD malposition (>40% of umbilical venous catheters and 37% of peripherally inserted central catheters at insertion) and migration (up to 36% of UVCs and 28% of neonatal PICCs), which can lead to serious complications including cardiac arrhythmias, vessel damage, hepatic extravasation, and cardiac tamponade. The Neonav has received FDA 510(k) clearance and is supported by two patents. The company has secured $4.3 million in funding and collaborates closely with clinicians in neonatal and pediatric intensive care units to develop clinically relevant solutions.

iMedrix Diagnostics Corp. is a medical device company headquartered in Northern New Jersey specializing in mobile cardiac care solutions. The company develops and markets KardioScreen™, a US FDA 510(k)-cleared, medical-grade mobile 12/6-lead ECG system that enables real-time cardiac monitoring and diagnosis. KardioScreen™ is cloud-connected, fully digital, and designed for bedside and remote monitoring applications, allowing clinicians to diagnose and manage cardiac conditions within minutes. The platform serves hospitals, clinics, and care providers seeking portable, economical alternatives to traditional fixed ECG systems. iMedrix targets both acute care settings and remote/home-based monitoring environments. The company emphasizes patient-centric design, regulatory compliance (FDA 510(k) clearance), and accessibility of cardiac diagnostics through innovative digital technology.

COSMED is an international medical technology company established in 1980 and based in Rome, Italy, specializing in diagnostic devices for cardiopulmonary, metabolic, and body composition assessment. The company designs, manufactures, and distributes a comprehensive range of diagnostic equipment serving hospitals, sports organizations, healthcare providers, and wellness centers across over 100 countries through direct offices and an extensive distributor network. COSMED's core product portfolio includes cardio pulmonary exercise testing (CPET) systems, indirect calorimetry devices, pulmonary function testing equipment, spirometers, body composition analyzers via air displacement plethysmography, stress testing ECG systems, and ergometers. Key brands include BOD POD, K4b2, Quark RMR, and Fitmate. The company serves multiple clinical specialties including pulmonology, cardiology, pediatrics, neonatology, critical care, and rehabilitation, while also supporting sports science, nutrition assessment, human performance evaluation, and wellness applications. COSMED provides integrated data management through its OMNIA software platform, which unifies metabolic, lung function, and body composition testing across the entire product ecosystem.

Nuwellis, Inc. is a commercial-stage medical device manufacturer specializing in ultrafiltration therapy systems for fluid management in cardiorenal patients. Founded in 1999 and headquartered in Eden Prairie, Minnesota, the company develops and markets the Aquadex FlexFlow System and Aquadex SmartFlow System—precision ultrafiltration devices designed to remove excess fluid in patients with heart failure, acute kidney injury, chronic kidney disease, and cardiorenal syndrome when diuretics prove inadequate. The systems deliver predictable, isotonic fluid removal while protecting organ function and reducing hospitalizations and readmissions. Nuwellis supports critical care, pediatric, nephrology, cardiology, and outpatient settings with comprehensive clinical evidence from 65+ peer-reviewed studies spanning 20+ years. The company provides integrated cardiorenal management solutions, clinical training, reimbursement support, and dedicated customer service to healthcare providers globally, addressing both acute perioperative fluid management and chronic disease management.

Advantech Corporation is a global leader in embedded computing, industrial automation, edge AI, and intelligent healthcare solutions. The company manufactures industrial-grade computing platforms, edge AI systems, IoT devices, and healthcare-specific IT infrastructure. Product lines include embedded PCs, fanless computers, edge AI and GPU systems, industrial motherboards, medical computers and tablets, medical monitors, and operating room video solutions. Advantech also provides intelligent healthcare platforms (iHospital), medical carts and tablets, and comprehensive design-to-order manufacturing services. The company serves industrial, healthcare, retail, logistics, and transportation sectors with solutions for edge computing, data acquisition, automation control, and healthcare IT infrastructure. Advantech offers design and manufacturing services, global technical support, RMA services, training through IoT Academy, and a comprehensive eStore for procurement. The company emphasizes reliability, industrial-grade specifications, and integration with industry standards.

Dalian Labtek Science & Development Co Ltd is a specialized medical device manufacturer headquartered in Dalian, China, with distribution presence in Brisbane, Queensland. Founded in 2006, the company focuses on pressure therapy and vascular intervention technologies, particularly in deep vein thrombosis (DVT) prevention and treatment. Labtek designs, manufactures, and exports advanced therapeutic pumps and endoscopic visualization systems for hospitals and healthcare facilities globally. The company maintains ISO 9001 and ISO 13485 quality management certifications, FDA approval for key product lines, CE marking for EU market access, and TÜV certification. With operations spanning over 50 countries including the United States, Germany, UK, Korea, Saudi Arabia, South Africa, and Brazil, Labtek serves as a recognized international supplier in the thrombosis prevention and vascular therapy domains. The company emphasizes innovation-driven product development and patient-centric clinical solutions.

Zywie, Inc. is a remote cardiac monitoring company delivering next-generation mobile cardiac telemetry (MCT) solutions for arrhythmia detection and continuous heart rhythm monitoring. The company manufactures the ZywieNano™ MCT Patch, a miniaturized biosensor worn as a patch for up to 30 days of continuous ECG monitoring. Core offerings include the patch device, a proprietary mobile application for patient engagement, AI-driven rhythm analysis (ZywieAI®), near real-time data transmission to clinicians, and 24/7 patient support services. The platform targets cardiology practices, primary care providers, and patients with suspected or known cardiac arrhythmias, atrial fibrillation, and syncope. Zywie's technology enables extended monitoring periods (15–30 days) versus traditional Holter monitors (24–48 hours), with integrated event logging, symptom tracking, and clinical decision support. The system provides advanced rhythm analysis including detection of ventricular tachycardia, atrial fibrillation, pauses, and bradycardia. The company serves 500,000+ patients and has processed over 1 trillion heartbeats. Regulatory status, specific FDA clearance details, and ISO certifications are not explicitly stated on the website. Zywie operates corporate headquarters in Johns Creek, Georgia and a clinical headquarters in Walnut Creek, California.

InfoBionic, Inc. is a virtual cardiac telemetry company specializing in AI-enabled remote cardiac monitoring. The company's flagship product, MoMe ARC® (Advanced Remote Cardiology), is recognized as the gold standard in remote cardiac ECG monitoring and represents the first platform to market with hospital-grade continuous monitoring capability deployable from nearly any location. The MoMe ARC® platform integrates advanced artificial intelligence to enhance clinical workflow, detect previously undetected cardiac anomalies, and enable rapid interventions at scale. InfoBionic offers a comprehensive suite comprising MoMe Solutions (AI-enabled ECG analysis), MoMe Sensors (interchangeable, tiered biosensor lead sets configurable for varying acuity levels from high-acuity diagnostics to portable monitoring), and MoMe Analytics™ (business intelligence and AI-embedded analytics for cardiac care operations). The company targets cardiology practices, cardiologists, electrophysiologists, medical leaders, hospital systems, and virtual health programs. InfoBionic has received FDA clearance for its MoMe ARC® Patch (announced August 2025), affirming regulatory compliance and clinical safety. The platform transforms cardiac data into actionable clinical insight through proprietary AI algorithms focused on arrhythmia detection, atrial fibrillation monitoring, and congenital heart disease assessment. Products are designed to improve patient quality of life through earlier interventions, enhance operational efficiency across departments, and support both enterprise and telehealth deployment models.

LumiQuick Diagnostics Inc. is a minority-owned, privately-held manufacturer of high-quality point-of-care testing and immunoassay kits for the global in vitro diagnostics market. Founded in 2006 and based in Santa Clara, California, the company develops rapid diagnostic tests in multiple formats including test cups, cards, dip tests, and multi-panels. Product lines span infectious disease detection (Dengue, Zika, Chikungunya, COVID-19), drugs of abuse screening, disease markers for cardiac and cancer indicators, fertility hormones, vitamin D assessment, oxidative stress measurement, veterinary diagnostics, food safety testing, and biological threat agent identification. LumiQuick's QuickProfile™ branded assays leverage immunochromatographic technology for qualitative and quantitative detection. The company also manufactures ELISA-based platforms and offers the FDA EUA-cleared Boson Rapid SARS-CoV-2 Antigen Home Test. Products are sold in bulk through local and international distributors, targeting clinical laboratories, point-of-care settings, and compliance screening applications.

Medeia Inc is a manufacturer and distributor of neurodiagnostic and cardiovascular physiological monitoring systems. Founded in 1992, the company specializes in state-of-the-art biometric hardware and software for autonomic nervous system assessment, vascular analysis, EEG/EEG-derived diagnostics, and sleep studies. Medeia's product portfolio serves neurologists, cardiologists, primary care physicians, and research institutions with comprehensive tools for objective physiological measurement, including autonomic function testing (ANS), pulse wave velocity analysis, peripheral neuropathy assessment, and neuroencephalography. The VitalScan product line addresses autonomic and vascular diagnostics; BrainView systems provide EEG and cognitive assessment; NeuroTrace offers ambulatory wireless EEG; SleepStudy delivers polysomnography; and CardioView supplies mobile cardiac telemetry. Products are designed for clinical workflow efficiency and are distributed internationally to healthcare providers and research facilities.

ACI Medical, LLC is a biomedical engineering firm specializing in non-invasive vascular diagnostic and therapeutic devices for patients with limb- and life-threatening vascular conditions. With over 30 years of experience, the company develops, manufactures, and distributes patented medical devices including the ArtAssist® Arterial Assist Device for peripheral arterial disease, diabetic foot ulcers, and critical limb ischemia; diagnostic tools such as the APG® Air Plethysmograph for venous disease assessment; and compression and augmentation devices like VenaPulse® and UnnaSleeve™. The company operates an FDA-registered contract manufacturing division producing miniature diaphragm pumps for medical and industrial applications, as well as custom plastic injection molding services. ACI Medical devices are available for home use and clinical settings, with strong relationships with VA hospitals nationwide.

Ivy Biomedical Systems is the market leader in precision cardiac and respiratory gating monitors and modules for diagnostic imaging synchronization. The company manufactures specialized equipment used to synchronize radiographic image acquisition across all major imaging modalities, including nuclear medicine/molecular imaging (NM/MI), computed tomography (CT), magnetic resonance (MR), positron emission tomography (PET), and single photon emission computed tomography (SPECT). Their gating solutions enable clinicians to acquire high-quality synchronized images by triggering image capture at specific cardiac or respiratory phases, reducing motion artifacts and improving diagnostic accuracy. The company serves as an OEM partner to major imaging equipment manufacturers and provides comprehensive sales, service, and technical support globally.

QT Medical, Inc. is a medical device manufacturer specializing in portable, wireless, cloud-connected 12-lead ECG systems for hospital-grade cardiac diagnostics and monitoring. Founded in 2013 and based in Diamond Bar, California, the company provides FDA-cleared solutions for both home-use self-monitoring and professional acute care settings. The QT ECG / PCA 500™ platform features pre-positioned sensors (QHeart®), AI-driven computer interpretation, and HIPAA-compliant cloud storage (ECGcloud®). Products are designed for patients from newborns to adults, reducing lead placement time by up to 70% and minimizing common errors such as limb-lead reversal. The company offers integrated mobile applications (iOS, Android, Windows) and cloud-based workflow management. QT Medical also provides Xpress ECG home delivery services and telemedicine-compatible solutions to enable accessible cardiac care across clinical and home environments.

BTL Industries is a global manufacturer of clinically proven medical and aesthetic equipment, operating since 1993 with headquarters in Prague and locations across 90+ countries. The company specializes in non-invasive therapeutic solutions for aesthetic medicine, rehabilitation and orthopaedics, cardiology and pulmonology, and advanced robotic medical systems. BTL's product portfolio encompasses body shaping and skin tightening devices, electrotherapy and ultrasound therapy systems, high-intensity laser therapy, cryotherapy, spinal decompression, cardiac monitoring and stress testing equipment, spirometry systems, and robotic rehabilitation solutions (R-GAIT, R-TOUCH, R-LEAD brands). The company serves diverse healthcare settings including small medical offices, multidisciplinary medical centers, hospitals, aesthetic clinics, and wellness centers. With approximately 3,700–4,000 employees including 500 engineers, BTL emphasizes clinical validation, technical reliability, comprehensive training programs, and after-sales support as core differentiators in the global medical device market.

Broadata Communications, Inc. (BCI) is a California-based medical device manufacturer specializing in professional AV connectivity and display solutions for healthcare and high-performance environments. Founded in 2000 and ISO 13485 certified, BCI delivers fiber optic video transport systems, HD-BaseT converters, HDMI 4K matrix switches, and medical-grade display technology including 32" 4K surgical displays and wireless monitor stands. The company provides comprehensive design engineering, kitting, and box build manufacturing services for demanding medical applications requiring reliable signal transmission over fiber, IP-based, and coaxial infrastructure. BCI has deployed over 500,000 products globally and serves medical facilities, surgical centers, defense, government, education, and entertainment sectors. Its core competency lies in engineered AV systems integration for operating rooms, diagnostic imaging, and telemedicine environments where signal integrity and compliance are mission-critical.

BioBridge Global is a remote patient monitoring platform specialized in cardiac device management for electrophysiology and cardiology practices. The company provides end-to-end remote monitoring services for patients with implanted pacemakers, defibrillators, and implantable cardiac monitors from major vendors including Abbott, Biotronik, Boston Scientific, and Medtronic. BioBridge handles patient scheduling, device connectivity, data collection and processing, daily clinical review by certified technicians and nurse practitioners, insurance verification and pre-authorization, and automated billing report generation. The platform integrates with major EHR systems (Epic, Meditech, Cerner, Allscripts, Athena, eClinical) and includes blood pressure and weight monitoring with 4G SIM-embedded devices. BioBridge operates as an extension of the practice, managing the complexity of cardiac device data transmission and clinical review while enabling practices to improve patient outcomes and increase remote monitoring revenue.

Clario (formerly Bioclinica) is a global clinical trial endpoint technology platform and services provider with 50+ years of expertise supporting drug development. The company delivers comprehensive solutions for efficacy, safety, and patient quality-of-life assessments across decentralized, hybrid, and site-based clinical trials in over 100 countries. Clario's integrated platform combines clinical trial management software, connected medical devices, and AI-powered solutions spanning cardiac safety monitoring, electronic clinical outcomes assessment (eCOA), medical imaging with imaging core lab services, precision motion analysis, and respiratory endpoints. With experience managing 30,000+ trials contributing to 700+ FDA/EMA new drug approvals, Clario employs 3,900+ professionals including 200+ therapeutic area specialists. The platform emphasizes regulatory compliance, patient-centric design, global multilingual deployment, and 24/7 operational support to simplify trial processes for sponsors, contract research organizations (CROs), and research sites.

Spacelabs Healthcare manufactures patient monitoring systems, diagnostic cardiology equipment, and clinical informatics solutions for acute care, ICU, emergency department, neonatal, and perioperative settings. Core product lines include bedside monitors (Xprezzon, Qube, C50), telemetry systems (AriaTele), central surveillance (Xhibit XC48, XC4), resting ECG systems (CardioExpress series 4012, 5012, SL18A, SL12A, SL6A), Holter monitors and event recorders (Eclipse Pro, Eclipse Mini, Pathfinder SL), and ambulatory blood pressure monitoring (OnTrak, 90217A). The company also offers clinical software tools including SafeNSound Care Coordination (SaaS), Clinical Access, Custom Trends, Print Manager, Smart Disclosure, and Vital Signs Viewer, along with networking and integration solutions (XprezzNet, Flexport interfaces) for EMR connectivity. Spacelabs emphasizes situation awareness design, clinical informatics, and care team performance optimization through its Runway architecture and TeamUp strategies. The company traces its heritage to NASA space program cardiac monitoring development and serves hospitals and healthcare systems across multiple care settings. Technical support includes product manuals, cleaning instructions, service contracts, and cybersecurity advisories.

Terumo Medical Corporation (North America division of Terumo Corporation, founded 1921) is a global leader in medical devices and supplies, headquartered in Somerset, NJ, with manufacturing operations in Elkton, MD and Caguas, PR. The company operates in 160 countries with 2,000+ North American associates supporting 30,000+ global employees. Terumo Medical manufactures injection and infusion therapy devices, safety syringes (including the SurTract™ Safety Syringe with SafeR® passive safety technology), and related products for human and animal health markets. The Terumo Interventional Systems (TIS) division specializes in minimally invasive solutions for cardiology, peripheral arterial disease, embolotherapy, and interventional oncology, providing entry site management, lesion access, and therapeutic intervention devices. Terumo Health Outcomes (THO) delivers operational and clinical decision support to hospitals and clinicians. The Pharmaceutical Solutions Division (PSD) provides design and development services. Terumo performs integrated R&D, manufacturing, marketing, distribution, and sales. The company is recognized as one of the world's leading medical device manufacturers, serving diverse healthcare markets with a focus on quality, innovation, and patient outcomes.

EUROIMMUN US Inc. is the North American subsidiary of Euroimmun, a leading German manufacturer of medical laboratory diagnostics founded in 1987. Operating in 18 countries with over 3,400 employees globally, the company specializes in innovative test systems, software, and automation solutions for diagnosing autoimmune diseases, infectious diseases, allergies, neurodegeneration, endocrinology, bone metabolism, and genetic analyses. Headquartered in Mountain Lakes, NJ, EUROIMMUN US supplies clinical laboratories with advanced immunodiagnostic reagents, microarray technologies, and chemiluminescence immunoassay (ChLIA) automation platforms. The company produces comprehensive antibody detection test systems and maintains ISO certifications, serving laboratory medicine professionals with high-quality, standardized diagnostic solutions for autoimmunity, infection control, and specialized clinical parameters.

ClariPi Inc. is a Seoul-based medical AI software company founded in 2015 specializing in deep-learning powered CT image denoising and diagnostic analysis solutions. The company develops vendor-neutral, FDA-cleared and CE-marked software that enhances CT image clarity while enabling ultra-low-dose imaging protocols across CT scanners from any manufacturer. ClariPi's portfolio includes ClariCT.AI (core denoising engine), ClariPulmo+ (lung nodule detection and COPD analysis), ClariSIGMAM (breast density assessment), ClariAdipo (abdominal fat composition analysis), ClariMetabo (metabolic risk quantification), ClariCardio (coronary artery calcium scoring and CVD risk), ClariOsteo (bone mineral density and fracture risk), and ClariACE (AI contrast enhancement). Products integrate via DICOM protocols with existing PACS systems and clinical workflows, supporting real-time processing from desktop, embedded scanner, or cloud deployment. The company partners with major healthcare systems, OEM CT manufacturers, and imaging centers to reduce radiation exposure while maintaining diagnostic confidence through advanced noise pattern recognition trained on millions of patient images.

Norav Medical is a cardiac diagnostic equipment manufacturer headquartered in Delray Beach, Florida, operating since 1993. The company specializes in electrocardiograph (ECG) systems and ancillary cardiology devices for hospitals, primary care practices, emergency departments, cardiology clinics, and clinical research settings. Product portfolio includes: Resting ECG systems (conventional and all-in-one models), Stress ECG with medical-grade treadmills and ergometers, Holter ECG for ambulatory monitoring, Ambulatory Blood Pressure Monitoring (ABPM), Spirometry systems for pulmonary function testing, ECG Telemetry/Cardiac Rehab monitoring systems, and a mobile ECG application (iOS, Android, Windows). The company also offers ECG management software with HL7, GDT, and DICOM connectivity for hospital information systems integration. Norav maintains FDA clearance, CE marking, MDSAP certification, ISO 13485 compliance, and HIPAA/GDPR data security certifications. Manufacturing emphasizes signal quality, automatic ECG interpretation, wireless and wired acquisition capabilities, and customizable solutions. The company provides localized technical support, on-demand service, custom software development, and equipment upgrade services. Key markets include acute-care hospitals, cardiology diagnostic centers, primary care offices, emergency medicine, and clinical trial research. The company serves diverse clinical segments with flexible, durable equipment designed for heavy use in challenging environments. In-house software development enables rapid customization and integration with existing hospital IT infrastructure.

Peerbridge Health is a cardiac diagnostics and remote monitoring company specializing in ambulatory ECG technology. The company develops the Cor platform, an FDA-cleared wearable ECG system designed for primary care clinics, cardiologists, and home use. Cor is a patented multi-lead, 2-channel wireless patch with Einthoven Triangle design that captures 31 cardiac rhythms with high-fidelity signal quality, enabling P-wave definition and QRS morphology analysis. The platform features proprietary algorithms to compute derived 12-lead ECG (under trial) and explainable AI markers for hospital-grade cardiac indications. Cor integrates into existing clinical workflows without administrative burden and maintains billing with the physician and clinic. The company is developing next-generation capabilities for structural cardiac assessment, functional performance monitoring, hemodynamic change detection, and autonomic/neurohormonal evaluation. Current clinical applications focus on early detection of heart failure, arrhythmia monitoring, and cardiac risk stratification in ambulatory and home settings. Peerbridge has announced FDA 510(k) submission for its next-generation Cor MDx device with wireless connectivity via AT&T partnership. The company operates research and development in Pasadena, California, with headquarters in Franklin, Tennessee. Clinical advisors include cardiologists and electrophysiologists from major health systems. The platform targets affordable, accessible cardiac diagnostics for populations currently underserved by traditional monitoring modalities.

Vielight Inc manufactures photobiomodulation (PBM) devices for consumer and clinical use, specializing in transcranial and intranasal light therapy systems targeting brain health and systemic wellness. The company's core technology uses safe, non-ionizing red and near-infrared light energy to stimulate mitochondrial ATP production, with applications in cognitive enhancement, neurological conditions, and immune support. Product lines include the Neuro series (Pro 2, Duo, Gamma, Alpha variants) for brain photobiomodulation targeting Alzheimer's disease, traumatic brain injury, Parkinson's disease, mild cognitive impairment, autism, and PTSD; the Vagus device for non-invasive vagal nerve stimulation; the MIP for systemic wellness and immunity; and the X-Plus for thymus stimulation. Vielight has published 30+ peer-reviewed studies in collaboration with leading institutions including UCSF, Harvard, University of Toronto, Boston University, and University of Utah, with 20+ ongoing clinical trials and 800+ research participants. The company holds Health Canada medical device approval and conducts FDA-regulated clinical studies. Devices are marketed directly to consumers, practitioners, athletes, and military/veteran populations. Manufacturing and logistics are based in Hayward, California; administration in Toronto, Ontario; and a USA sales office in Shepherdstown, West Virginia. Over 100,000 devices sold globally with a 4.8/5 customer rating.

inomed Inc., USA is the US subsidiary of inomed Medizintechnik GmbH, a German medical device manufacturer with 30+ years of expertise in intraoperative neuromonitoring (IOM). The company specializes in complete IOM solutions for Head & Neck surgical procedures, providing systems, accessories, and on-site support to surgeons and healthcare facilities. Their core product line includes the C2 NerveMonitor and associated monitoring accessories designed to enhance patient and surgeon safety during surgery by enabling real-time neurophysiological monitoring. Manufacturing adheres to German quality standards, and the company emphasizes direct customer support, comprehensive service packages, and worldwide distribution capabilities. inomed serves specialists globally and has supported millions of patients through its neurophysiological monitoring technology. The company operates an e-commerce platform for orders and provides both hardware systems and consumable accessories for intraoperative monitoring applications.

Baxter Healthcare Corporation is a global medical device and pharmaceutical company serving hospitals, physician offices, and home care settings. The company manufactures and distributes essential solutions across primary care, hospital care, surgical care, nutritional care, and respiratory care. Baxter's portfolio includes infusion pumps and IV delivery systems (notably used in chemotherapy and critical care), cardiac monitoring and vital signs equipment, ventilators and oxygen therapy devices, nutritional support products, and vision screening systems. The company emphasizes connected care and digital health integration, addressing the fragmentation of isolated medical devices through data connectivity and clinical workflow optimization. Baxter serves inpatient acute care, intensive care units, operating rooms, outpatient clinics, and home healthcare environments. The company has over 90 years of operational history and maintains substantial manufacturing and supply chain capabilities. Products are designed for use by nurses, physicians, and other clinical staff in hospitals, ICUs, surgical suites, and residential settings. Baxter's regulatory footprint includes FDA-cleared and internationally approved devices. The organization operates under a mission framework emphasizing patient safety, clinical efficiency, and care outcomes improvement.

Avery Biomedical Devices manufactures the Avery Diaphragm Pacing System, a fully implantable phrenic nerve stimulator designed to provide vent-free breathing for patients with chronic respiratory muscle paralysis or central alveolar hypoventilation. The system consists of surgically implanted receivers and electrodes that respond to radio frequency signals from an external transmitter and antennas, stimulating the diaphragm to contract and enable natural breathing. Indications include high spinal cord injury, congenital and acquired central sleep apnea, and diaphragm paralysis from various etiologies. The device features dual redundant design ensuring no single-point failure, platinum electrodes, and dual alarm systems. The company holds FDA PMA approval for adult and pediatric use and CE marking privileges for EU markets. Key benefits include improved quality of life with greater mobility, reduced infection and hospitalization risk, lower annual operating costs (estimated $20,000+ savings versus mechanical ventilation), minimal ongoing wound care, and compatibility with water therapy. Technical support is provided at no additional cost. Reimbursement is available through Medicare and most private and government insurance plans. Avery has maintained an unsurpassed safety and reliability record spanning over 50 years of clinical use. The system is indicated for patients whose remaining phrenic nerve, lung, and diaphragm function is sufficient to accommodate electrical stimulation.

Caristo Diagnostics is a cardiac imaging AI software company that develops proprietary technology to detect coronary inflammation and assess cardiovascular disease risk from coronary CT angiography (CCTA) imaging. The company's flagship platform, CaRi-Heart® Technology, combines AI-driven analysis with clinical cardiology to enable early detection of hidden inflammation associated with heart attack risk. Key product offerings include FAI-Score™ (Functional Assessment of Inflammation score for detecting coronary inflammation), CaRi-Plaque™ Analysis (quantifying and characterizing coronary plaque burden), and Individualised Risk Score (predicting cardiac events). Caristo serves multiple clinical applications: preventive screening for asymptomatic patients, disease diagnosis and risk stratification, drug clinical trials (as an imaging core lab), and intervention planning. The company has FDA 510(k) clearance, CPT code recognition from the American Medical Association, and demonstrated clinical utility through publications in The Lancet and presentations at major cardiology conferences (AHA, SCCT). Caristo operates imaging analysis centers globally and partners with leading pharmaceutical companies for atherosclerotic cardiovascular disease (ASCVD) trials. The company is positioned as a digital health innovator focused on transforming preventive cardiology through quantitative imaging biomarkers of coronary inflammation.

MDF Instruments Craftech LLC is a Puerto Rico-based manufacturer and distributor of diagnostic stethoscopes and medical apparel, headquartered in Rincón, PR. Founded in 1971, the company specializes in high-quality stethoscopes across multiple product lines including the ProCardial® Titanium (cardiology-grade), MD One® (dual-head adult), MD One® Epoch® (titanium), and Mprint® (printed/patterned) collections. Products feature titanium and stainless steel construction with color options, finish variants (rose gold, blackout, kaleidoscope), and decorative patterns (animal prints, tie-dye, glitter, camouflage, floral). The company also distributes scrubs and medical apparel from brands including Cherokee, Healing Hands, and OliveUs. MDF Instruments serves healthcare professionals, clinical settings, and allied health markets through direct B2C e-commerce and distribution channels. The site emphasizes product durability, acoustic clarity for diagnostic use, and aesthetic customization. Manufacturing and assembly operations are based in Puerto Rico. No specific FDA clearances, ISO certifications, or 510(k) information is disclosed on the current website.

inHEART develops an AI-enabled digital twin platform for cardiac care, specializing in image-guided ablation procedures for ventricular tachycardia (VT) and other arrhythmias. The company's core offering is a proprietary segmentation algorithm that analyzes CT and MR images to create detailed 3D anatomical cardiac models, enabling precise identification of arrhythmogenic tissue and substrate characterization. The platform integrates seamlessly with all major electroanatomic mapping (EAM) systems for real-time procedural guidance. Clinical evidence demonstrates 60% reduction in procedure time and 38% reduction in recurrence rates for VT ablations. inHEART serves 300+ partner hospitals across 40+ countries, with 7,500+ supported cases. The company maintains regulatory compliance including SOC 2 and HIPAA certifications. Based in France (Bordeaux/Pessac) with a US office in Cambridge, MA, inHEART operates at the intersection of advanced imaging analytics, AI, and interventional cardiology. The platform has been featured in major cardiac electrophysiology symposia and publications, with endorsements from leading academic electrophysiologists. Recent funding (2024) and board leadership appointments signal continued investment in platform expansion and global market penetration. Target users include cardiac electrophysiologists, interventional cardiologists, and hospital EP labs managing complex arrhythmias.

Ventric Health manufactures the Vivio® System, an FDA-cleared Class II medical device for non-invasive heart failure diagnosis in primary care settings. The Vivio System uniquely measures left ventricular end-diastolic pressure (LVEDP)—the clinical hallmark of heart failure—using a portable, point-of-care approach combining brachial cuff and ECG technology. The system delivers results in under five minutes and integrates the Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12) to assess patient symptoms and disease burden. Approximately 70% of patients identified with elevated LVEDP exhibit Stage C heart failure symptoms, while 30% present Stage B findings. The Vivio System demonstrates superior specificity and sensitivity compared to traditional clinical indicators, enabling clinicians to identify at-risk patients earlier and initiate guideline-directed medical therapy more promptly. Target markets include primary care physicians, cardiologists, Medicare ACOs, healthcare systems, and Medicare Advantage plans. The company has established partnerships with leading health systems including Agilon Health, AltaMed, Desert Oasis Healthcare, Heritage Victor Valley Medical Group, and Regal Medical Group. Ventric Health is based in Pasadena, California, and operates through clinical validation studies published in peer-reviewed journals including JACC: Advances and the Journal of the American Heart Association.

Nasiff Associates, Inc. is a US-based medical technology manufacturer specializing in PC-based ECG (electrocardiogram) diagnostic systems. Founded in 1989 and veteran-owned, the company designs and manufactures CardioCard ECG systems for use in hospitals, clinical offices, telehealth platforms, and home-based medical services. All devices are manufactured domestically in the United States and feature integrated software designed to connect with major EMR systems via the proprietary Cardio Universal EMR Interface. The product line includes resting ECG machines, stress testing systems, and Holter monitoring devices, all running on a unified software platform that allows clinicians to manage multiple diagnostic ECG modalities through a single interface. Nasiff markets its solutions as providing accurate signal acquisition, reliable interpretation, and meaningful clinical decision-making support for cardiovascular disease screening and management. The company emphasizes all-American sales and technical support, with a dedicated US-based customer support team providing live technical assistance. FDA clearance is obtained for its devices, and the company holds veteran-owned small business status.

Boston Scientific Corporation is a global medical device manufacturer serving multiple clinical specialties including cardiology, urology, gastroenterology, interventional radiology, electrophysiology, neurology, pain management, vascular surgery, and structural heart disease. The company manufactures and distributes a broad portfolio of minimally invasive medical devices, including cardiac rhythm management systems, interventional cardiology devices, electrophysiology catheters and mapping systems, spinal cord stimulation systems for pain management, urological devices, endoscopy and visualization systems, defibrillators, and interventional oncology equipment. Boston Scientific operates a healthcare professional portal providing online training through EDUCARE, e-commerce ordering, reimbursement resources, and comprehensive customer support with specialty-specific representative contact networks. The organization serves hospitals, ambulatory surgery centers, and healthcare professionals across the United States through direct sales and support teams organized by medical specialty. Products undergo rigorous regulatory compliance (FDA 510(k), international certifications) and the company emphasizes quality assurance and product safety as core organizational values. Customer care is available via a dedicated U.S. customer service line, with extended business hours Monday–Friday.

Aventusoft, LLC is a Boca Raton, Florida-based medical technology company specializing in signal detection analysis and AI-driven digital health platforms since 2010. The company develops innovative solutions focused on cardiac monitoring, clinical decision support, and decentralized clinical research. Primary product lines include Hemotag, a non-invasive cardiac monitoring device paired with AI analytics to reduce reliance on invasive cardiac imaging and implantable devices; CarePear, a digital health platform connecting patients and physicians with US-based sub-specialists through AI-enabled telemedicine; and Trialogy, an AI-driven platform for decentralized clinical trials that streamlines life science research. Aventusoft has received recognition from the NIH (RADx Tech for Maternal Health Challenge), DARPA, American College of Cardiology (ACC Innovation Showcase Award 2021 and 2023), and multiple design and innovation awards. The company demonstrated 146% two-year revenue growth and ranked No. 112 on Inc. Magazine's 2023 Southeast Region fastest-growing private companies list. Products target cardiac care, maternal health, specialist access, and clinical research domains, with regulatory focus on maternal health applications and AI-driven diagnostics.

Icentia is a medical devices manufacturer and service company specializing in innovative solutions for long-term cardiac monitoring and ECG testing in institutional healthcare settings. The company's flagship product is CardioSTAT®, a compact, lightweight, and patient-comfortable continuous ECG recorder designed for ambulatory cardiac rhythm diagnosis. CardioSTAT features high-quality single-lead ECG recordings optimized for extended wear, combining clinical accuracy with superior patient compliance. The device has achieved FDA clearance in the United States and is used extensively across Canadian academic medical centers and cardiac institutes. Icentia has established partnerships with leading academic institutions including Institut Universitaire de Cardiologie et de Pneumologie de Québec, Institut de Cardiologie de Montréal, Ottawa Heart Institute, and Hamilton Health Sciences. The company has demonstrated significant growth, ranking among Canada's top growing companies for four consecutive years (2019–2022). Icentia maintains robust data collection and analysis capabilities, having compiled the largest public single-lead ECG dataset of 11,000 patients with 2 billion annotated beats. The CardioSTAT system has surpassed 100,000 completed tests, establishing clinical credibility in arrhythmia detection and continuous cardiac monitoring. The company operates as both a device manufacturer and service provider, leveraging partnerships with research institutions including Mila (Montreal Institute for Learning Algorithms). Icentia serves institutional healthcare markets across North America with a focus on cardiac diagnostic excellence and clinician-friendly workflow integration.

Piccolo Medical designs and manufactures guidance systems for peripherally inserted central catheter (PICC) and central venous catheter (CVC) placement. The company's flagship products—PM2+™ System and ECGuide®—use intravascular electrocardiogram (ECG) technology combined with ionic dilution sensing to enable bedside confirmation of catheter tip positioning, eliminating the need for post-placement chest X-ray confirmation. The PM2+™ System features the Nav+™ stylet with machine learning-powered navigation feedback delivered via a mobile app; setup takes under 90 seconds and provides real-time guidance during catheter insertion. ECGuide® is cleared for use in adult, pediatric, and neonatal patients and has been shown to improve placement accuracy and reduce complications including thrombosis and malposition. The technology addresses a significant clinical and operational problem: approximately 50% of PICCs placed without guidance are malpositioned, requiring confirmatory imaging that adds cost, radiation exposure, and procedure time (average 78-minute wait for chest X-ray). Piccolo Medical is FDA 510(k) cleared and has received funding from the National Institute on Aging (NIA) and other federal agencies. The company serves hospitals and healthcare systems focused on improving catheter placement safety and reducing procedural delays.

ScottCare Corporation is a leading provider of cardiopulmonary rehabilitation monitoring and management systems. For over 25 years, the company has served more than 2,200 rehabilitation centers nationwide with innovative solutions for cardiac and pulmonary patient monitoring and care coordination. ScottCare's core product portfolio includes VersaCare, a monitoring system for cardiac and pulmonary rehabilitation programs, and Aermos, a comprehensive, purpose-built cardiopulmonary rehab management system designed for modern clinical workflows. Aermos provides charting, team collaboration tools, and real-time access to patient data with a scalable, cloud-enabled architecture. The company maintains 1,365 EHR integrations, enabling seamless data exchange with hospital electronic medical record systems via HL7 standards. ScottCare's solutions are used by hospital rehabilitation departments, cardiac rehab programs, and pulmonary function testing centers. The company offers equipment servicing and technical support through dedicated teams, including domestic and international service capabilities. ScottCare demonstrates commitment to clinical advocacy, participating in industry events such as Day on the Hill and the CEPA Annual Conference. The company emphasizes real-time reporting, provider access to patient data, and continuous system upgrades. While specific FDA or ISO certifications are not detailed on the fetched content, the company's long market presence and widespread adoption indicate regulatory compliance in the US medical device space.

U S Vascular manufactures arterial Doppler physiologic testing systems and vascular diagnostic equipment, primarily the VascuLab product line. The company specializes in vascular medicine technology designed by and for vascular technologists, offering two core platforms: the VascuLab 4040 GSX and VascuLab 4040. Both systems provide spectral Doppler ultrasound, photoplethysmography (PPG), segmental pressure measurements, and plethysmography capabilities for vascular labs and hospitals. Key differentiators include ergonomic variable-height carts, medical-grade antimicrobial 24-inch touch-screen computers with sealed washable keyboards, wireless battery operation (8–16 hours per charge), ultra-stable PPG probes, 12-channel automated cuff inflation, and intuitive software with 24-function wireless remote controls. The GSX model emphasizes ergonomics for large hospital labs; the 4040 features a rugged aluminum cart for heavy-duty mobility. Systems include FDA-approved bayonet connectors, hi-res USB cameras for patient documentation, and support for bedside portable examinations without electrical constraints. U S Vascular offers integrated sales and support with emphasis on customer feedback loops and continuous technology enhancement. The company provides software downloads, technical support, and positioning within professional vascular societies (SVU, SDMS, SVM, SVS, AIUM, ACP) and credentialing bodies (IAC, ARDMS, CCI).

MicroPort CRM is a pioneering cardiac rhythm management company with world headquarters in Clamart, near Paris, France. The company develops, manufactures, and markets a comprehensive portfolio of cardiac devices for the management of cardiac rhythm disorders and heart failure globally. Product lines include cardiac pacemakers, implantable cardiac defibrillators (ICDs), cardiac resynchronization therapy (CRT) systems, and ECG diagnostic solutions. MicroPort CRM serves healthcare professionals and patients worldwide, offering not only advanced medical devices but also education, training programs, and clinical support. The company emphasizes connectivity in cardiac care and maintains a commitment to ethical practices and stakeholder engagement. As a specialized cardiac device manufacturer, MicroPort CRM operates under stringent regulatory frameworks governing implantable medical devices, including FDA clearances and international certifications required for pacemakers, defibrillators, and resynchronization therapies. The company's business model encompasses product development, manufacturing, clinical education, and healthcare professional training to support optimal patient outcomes in cardiac rhythm management.

Global Instrumentation, LLC provides customized cardiac diagnostic and monitoring solutions for clinical researchers, contract research organizations, core labs, remote cardiac monitoring service providers, and medical technology OEMs. The company specializes in precision ECG data collection, ambulatory blood pressure monitoring (ABPM), and enterprise-level data management platforms for cardiac safety assessment in clinical trials (Phase 1–5). Product portfolio includes the M5 Wearable ECG Recorder (ultra-compact, 21-day ambulatory recording capability), M12R Holter & ECG Recorder (simultaneous 12-lead real-time and long-term monitoring), M12R Lite (portable 12-lead acquisition with Bluetooth connectivity), M12A Enterprise Software Platform (scalable cloud-based data acquisition, management, and analysis system for ECG and ABP data), and Oscar 2 Ambulatory Blood Pressure Monitor (24-hour ABPM standard). The M12A platform integrates multiple devices and enables centralized data collection, analytics, reporting, and secure storage across geographically distributed trials. Solutions are used in thousands of clinical trials globally. The company emphasizes patient-friendly device design, flexible cloud deployment, precision analytics, and streamlined regulatory submission workflows. Services include custom software development and OEM partnerships for cardiac sensors and monitoring systems.

Turing Medical is a precision brain mapping and neuromodulation therapy company. The company develops PACE (Personalized Adaptive Cortical Electro-Stimulation), a precision-guided neuromodulation therapy platform designed to treat severe depression and chronic pain through adaptive cortical stimulation. PACE combines precision functional mapping with cortical stimulation, intended to restore healthy brain activity without the invasiveness of deep brain surgery—analogous to how a pacemaker restores cardiac rhythm. The company was formerly known as Nous Imaging and is led by co-founders Nico Dosenbach, M.D., PhD and Damien Fair, PA-C, PhD, both neuroscience researchers with published work in Nature on brain plasticity and precision functional mapping. Turing Medical's research focuses on reproducible brain-wide association studies, precision dynamical mapping, and mind-body network discovery. The company has appointed Kevin King, a medtech executive with three decades of experience in precision medicine and diagnostic technologies, as President and CEO as of April 2025, signaling expansion into clinical applications and commercialization. Turing Medical serves the neurology, psychiatry, and pain management markets. The company's technology platform leverages advanced functional brain imaging and mapping capabilities to enable personalized treatment targeting.

CVRx is a medical technology company specializing in neuromodulation therapies for heart failure management. The company's flagship product, Barostim, is an implantable device that delivers gentle electrical pulses to baroreceptors on the carotid artery to modulate neural signals and reduce heart failure symptoms. Clinical evidence demonstrates that Barostim improves exercise capacity (patients walk approximately 60 yards farther in 6-minute testing), quality of life (3x greater improvement vs. medication alone), and symptom relief, with 94% of patients experiencing significant improvement in quality of life, exercise capacity, or heart failure symptoms. The minimally invasive implant procedure typically takes about one hour with same-day discharge and a 97% freedom-from-complications rate. CVRx provides comprehensive support services to healthcare providers, including patient access assistance and reimbursement support to ensure eligible patients can access baroreflex activation therapy.